High IP-10 Levels Decrease T Cell Function in HIV-1-infected Individuals on ART

Overview

Journal J Leukoc Biol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2014 Aug 27

PMID 25157027

Citations 34

Authors

L A Ramirez

T A Arango

E Thompson

M Naji

P Tebas

J D Boyer

Affiliations

Soon will be listed here.

Abstract

HIV-1-infected subjects, despite control of viral replication with ART, have an altered immune cytokine/chemokine milieu. Changes in systemic cytokines and chemokines can alter immune responses. IP-10, in particular, has been associated with pathogenesis in a number of conditions, and we found that IP-10 is increased in serum in subjects who are HIV-1 infected and on stable ART compared with HIV-1-uninfected individuals. In a series of in vitro studies, we found that PBMCs exposed to IP-10 showed a significant decrease in the number of cells capable of secreting IFN-γ, as well as other cytokines, when stimulated with recall antigens. Furthermore, treatment with IP-10 led to decreased antigen-specific calcium signaling and MAPK38 phosphorylation. Importantly, the cytokines, as well as proliferative responses, could be enhanced with an IP-10 Nab. Our findings suggest that IP-10-modulating drugs may potentially enhance T cell responses to vaccination and HIV-1 in HIV+ subjects on ART.

Citing Articles

Characteristics of cytokines/chemokines associated with disease severity and adverse prognosis in COVID-19 patients.

Cheng J, Wang H, Li C, Yu J, Zhu M Front Immunol. 2024; 15:1464545.

PMID: 39654886 PMC: 11625740. DOI: 10.3389/fimmu.2024.1464545.

Regulatory role of microRNAs in virus-mediated inflammation.

Baghi H, Bayat M, Mehrasa P, Alavi S, Lotfalizadeh M, Memar M J Inflamm (Lond). 2024; 21(1):43.

PMID: 39497125 PMC: 11536602. DOI: 10.1186/s12950-024-00417-7.

Human induced pluripotent stem cell-derived cardiomyocytes to study inflammation-induced aberrant calcium transient.

Tatekoshi Y, Chen C, Shapiro J, Chang H, Blancard M, Lyra-Leite D Elife. 2024; 13.

PMID: 39331464 PMC: 11434618. DOI: 10.7554/eLife.95867.

The Role of MicroRNAs in HIV Infection.

Morando N, Rosenzvit M, Pando M, Allmer J Genes (Basel). 2024; 15(5).

PMID: 38790203 PMC: 11120859. DOI: 10.3390/genes15050574.

Aging modifies endometrial dendritic cell function and unconventional double negative T cells in the human genital mucosa.

Parthasarathy S, Shen Z, Carrillo-Salinas F, Iyer V, Vogell A, Illanes D Immun Ageing. 2023; 20(1):34.

PMID: 37452337 PMC: 10347869. DOI: 10.1186/s12979-023-00360-w.

References

Aberg J . Aging, inflammation, and HIV infection. Top Antivir Med. 2012; 20(3):101-5. PMC: 6148943. View

Lee E, Lee Z, Song Y . CXCL10 and autoimmune diseases. Autoimmun Rev. 2008; 8(5):379-83. DOI: 10.1016/j.autrev.2008.12.002. View

Liu M, Guo S, Hibbert J, Jain V, Singh N, Wilson N . CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 2011; 22(3):121-30. PMC: 3203691. DOI: 10.1016/j.cytogfr.2011.06.001. View

Boyer J, Robinson T, Kutzler M, Parkinson R, Calarota S, Sidhu M . SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol. 2005; 34(5-6):262-70. DOI: 10.1111/j.1600-0684.2005.00124.x. View

Soderholm J, Waldenstrom J, Askarieh G, Pilli M, Bochud P, Negro F . Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. PLoS One. 2013; 8(2):e56991. PMC: 3577643. DOI: 10.1371/journal.pone.0056991. View

Migueles S, Weeks K, Nou E, Berkley A, Rood J, Osborne C . Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol. 2009; 83(22):11876-89. PMC: 2772718. DOI: 10.1128/JVI.01153-09. View

Rahman S, Connolly J, Manuel S, Chehimi J, Montaner L, Jain P . Unique Cytokine/Chemokine Signatures for HIV-1 and HCV Mono-infection versus Co-infection as Determined by the Luminex® Analyses. J Clin Cell Immunol. 2011; 2(1). PMC: 3134230. DOI: 10.4172/2155-9899.1000104. View

Luster A, Ravetch J . Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med. 1987; 166(4):1084-97. PMC: 2188708. DOI: 10.1084/jem.166.4.1084. View

Deeks S . HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2010; 62:141-55. PMC: 3759035. DOI: 10.1146/annurev-med-042909-093756. View

10.

Sajadi S, Khoramdelazad H, Hassanshahi G, Rafatpanah H, Hosseini J, Mahmoodi M . Plasma levels of CXCL1 (GRO-alpha) and CXCL10 (IP-10) are elevated in type 2 diabetic patients: evidence for the involvement of inflammation and angiogenesis/angiostasis in this disease state. Clin Lab. 2013; 59(1-2):133-7. DOI: 10.7754/clin.lab.2012.120225. View

11.

Newton P, OBoyle G, Jenkins Y, Ali S, Kirby J . T cell extravasation: demonstration of synergy between activation of CXCR3 and the T cell receptor. Mol Immunol. 2009; 47(2-3):485-92. PMC: 2817451. DOI: 10.1016/j.molimm.2009.08.021. View

12.

Papanicolaou D, Wilder R, Manolagas S, Chrousos G . The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998; 128(2):127-37. DOI: 10.7326/0003-4819-128-2-199801150-00009. View

13.

Charles E, Dustin L . Chemokine antagonism in chronic hepatitis C virus infection. J Clin Invest. 2010; 121(1):25-7. PMC: 3007165. DOI: 10.1172/JCI45610. View

14.

Lacotte S, Brun S, Muller S, Dumortier H . CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci. 2009; 1173:310-7. DOI: 10.1111/j.1749-6632.2009.04813.x. View

15.

Katlama C, Deeks S, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C . Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013; 381(9883):2109-17. PMC: 3815451. DOI: 10.1016/S0140-6736(13)60104-X. View

16.

Campbell J, Gangur V, Simons F, HayGlass K . Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop. FASEB J. 2003; 18(2):329-31. DOI: 10.1096/fj.02-0908fje. View

17.

Gratton J, Morales-Ruiz M, Kureishi Y, Fulton D, Walsh K, Sessa W . Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J Biol Chem. 2001; 276(32):30359-65. DOI: 10.1074/jbc.M009698200. View

18.

Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A . Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest. 2010; 121(1):308-17. PMC: 3007131. DOI: 10.1172/JCI40594. View

19.

Casrouge A, Bisiaux A, Stephen L, Schmolz M, Mapes J, Pfister C . Discrimination of agonist and antagonist forms of CXCL10 in biological samples. Clin Exp Immunol. 2011; 167(1):137-48. PMC: 3248095. DOI: 10.1111/j.1365-2249.2011.04488.x. View

20.

Chen L, Lv J, Wen X, Niu J . CXC chemokine IP-10: a key actor in liver disease?. Hepatol Int. 2015; 7(3):798-804. DOI: 10.1007/s12072-013-9445-0. View